BI 860585

Drug Profile

BI 860585

Alternative Names: BI-860585

Latest Information Update: 01 Apr 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharmaceuticals; Evotec AG
  • Developer Boehringer Ingelheim Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2016 Phase-I development is ongoing in Belgium and Italy
  • 23 Sep 2013 Phase-I clinical trials in Solid tumours in Italy & Belgium (PO)
  • 05 Sep 2013 Boehringer Ingelheim Pharmaceuticals plans a phase I trial in Solid tumours (late-stage disease, second-line therapy or greater) in Belgium and Italy (NCT01938846)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top